Aculys Pharma signed an exclusive licensing agreement with Neurelis, Inc. for the development and commercialization of VALTOCO®
Aculys Pharma signed an exclusive licensing agreement with Neurelis, Inc. for the development and commercialization of VALTOCO® (diazepam nasal spray), a nasal spray approved by the FDA in the United States for the acute treatment of seizure clusters in patients with epilepsy six years of age and older. There are currently no approved nasal sprays available […]
Aculys Pharma Closes US$60 Million Series A Financing Led by SoftBank Vision Fund 2
Aculys Pharma, Inc. (“Aculys Pharma”), a new biopharmaceutical company focused on the development and commercialization of new innovative drugs in the fields of neurology and psychiatry, today announced the closing of a US$60 million Series A financing led by SoftBank Vision Fund 2 and joined by Catalys Pacific, HBM Healthcare Investments, Global Founders Capital, Sumitomo […]
The New England Journal of Medicine publishes the results of the NATIVE Phase IIb clinical trial with lanifibranor in NASH
Inventiva announces the initiation of its pivotal Phase III clinical trial evaluating lanifibranor in NASH
Inventiva receives FDA Breakthrough Therapy designation for lead drug candidate lanifibranor in NASH
Inventiva’s lanifibranor meets the primary and key secondary endpoints in the Phase IIb NATIVE clinical trial in non-alcoholic steatohepatitis (NASH)